Nabriva Therapeutics plc (NASDAQ:NBRV) traded at $0.6879 at last check on Monday, June 29, making a downturn move of -2% on its previous day’s price.
Looking at the stock we see that its previous close was $0.7 and the beta (5Y monthly) reads 2.55 with the day’s price range being $0.6702 – 0.6950. In terms of its 52-week price range, NBRV has a high of $2.77 and a low of $0.485. The company’s stock has gained about -17.77% over that past 30 days.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $400Million, with a low of $200Million and a high of $700Million. The median projection represents growth adding up to -23.8% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $5.05 Million, or -46.7% down from figures reported last year.
There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the NBRV stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Based on estimates by 6 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the Nabriva Therapeutics plc (NBRV) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the NBRV stock currently stands at 0, and the current price level is -14.8% off its SMA20 and -1.31% from its 50-day simple moving average. The RSI (14) is pointing at 43.86 while the volatility over the past week is 11.83% and jumps to 14.46% over the past one month. The beta value is 2.41, while the average true range (ATR) is currently pointing at 0.11. The average price target for the stock over the next 12 months is $1.5, with the estimates having a low of $1 and a high of $2. These price ends are 45.37% and +190.74% off the current price level respectively, although investors could be excited at the prospect of a +118.05% if the NBRV share price touches on the median price of $1.5.
Let’s briefly compare Nabriva (NBRV) stock to its peers. We find that today’s price change of -2% and -68.47% over the past 12 months for NBRV competes that of Amgen Inc (AMGN), which has seen its stock price fall -0.56% in the latest trading session and is +26.53% over the last one year. Another of its peers Gilead Sciences Inc (GILD) has climbed 0.7% today, and is +11.17% up over the past year, while Vertex Pharmaceutic (VRTX) is also down -2% yet its price remains in the red at -68.47% over the same period. Amgen has a P/E ratio of 18.24 compared to Nabriva’s 0 and Gilead’s 19.17. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.81% and 1.11%, respectively, in early deals.
Coming back to Nabriva Therapeutics plc (NASDAQ:NBRV), we note that the average 3-month trading volume was 6.86 Million, while that of the preceding 10-day period stands at 12.2 Million. Current shares outstanding are 142.96 Million.
According to data from Thomson Reuters, insiders hold 1.23% of the company’s shares while institutions hold 43.41%. The data shows that short shares as of June 14, 2020, stood at 6.46 Million at a short ratio of 0.59. This represents a 4.52% Short interest in Shares outstanding on June 14, 2020. Shares short rose in June from the previous month at 2.96 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -46.97% down in year-to-date price movement.